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A B S T R A C T
Objective: To evaluate the 2-year clinical outcomes of XIENCETM V everolimus eluting stent (EES) for the
treatment of coronary artery disease.
Background: Percutaneous coronary intervention with a drug eluting stent has become the preferred
treatment in patients with coronary artery disease. Everolimus eluting stent had proven efﬁcacy in
randomized control trials but those trials may not represent daily practice of interventional cardiology.
Methods: The THRIVE study was a prospective, multicenter, real-world, single-arm registry. Included in
the registry were 400 patients in Thailand with coronary artery disease suitable for treatment with the
XIENCETM V.
Results: At 30 days, 1 year, and 2 years, the respective rate of all-cause mortality, myocardial infarction
(MI), and target lesion revascularization (TLR) was 0.7, 1.0, and 0.5 %. 2.1, 2.1, and 1.0 %, and 2.2, 3.0, and
2.1 %. The cumulative rate for stent thrombosis was 1.6 % at 2 years.
Conclusions: The THRIVE study demonstrated that use of EES yielded a rate for 2 years of major adverse
cardiac events comparable to the randomized controlled trial of EES in the SPIRIT trials. This result
supports the efﬁcacy and safety of XIENCETM V everolimus eluting for daily interventional cardiology
practice.
 2016 Published by Elsevier B.V. on behalf of Cardiological Society of India. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Drug eluting stents (DES) have become a standard device for
reducing the rate of re-stenosis among patients undergoing
percutaneous coronary intervention (PCI).1 The major concern is
the complications related to the delayed vascular healing effect of
DES. The most serious complications are stent thrombosis,
myocardial infarction, and cardiac death. Recent randomized
controlled trials have provided signiﬁcant information regarding
the efﬁcacy and safety of new DES compared to controlled devices.
The limitation of highly selective eligibility criteria in those* Corresponding author at: Division of Cardiology, Faculty of Medicine, Khon
Kaen University, Khon Kaen 4002, Thailand.
E-mail address: sonkia@kku.ac (S. Kiatchoosakun).
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creativecommons.org/licenses/by-nc-nd/4.0/).randomized controlled trials have raised questions about efﬁcacy
and safety issues of DES in daily practice of interventional cardiology.
Coronary artery disease is one of the leading causes of death in
Thailand. PCI has emerged as a revascularization treatment choice
for patients with coronary artery disease in the past 10 years.2
Notwithstanding, the data on the outcomes among Thai people
treated with DES are not available. The feasibility and efﬁcacy of
XIENCE V (Abbott Vascular, Santa Clara, California) everolimus
eluting stent (EES) were evaluated in the SPIRIT FIRST (The Abbott
XIENCE V Everolimus Eluting Coronary Stent System in the
Treatment of Patients with de Novo Native Coronary Artery
Lesions). That trial demonstrated a signiﬁcant reduction in rate loss
of stents compared to bare-metal stents.3 The XIENCE V EES was
further evaluated in the SPIRIT clinical trails program, which
suggested superior clinical outcomes compared to TAXUS pacli-
taxel eluting stents (PES).4 The objective of the present study wasluation of the XIENCE V everolimus eluting stent in the treatment
 – XIENCE V performance evaluation (THRIVE study), Indian Heart
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EES in a Thai population.
2. Materials and methods
THRIVE was a prospective, multicenter, single-arm registry in
Thailand. The study was designed to enroll 400 patients from
4 sites in Thailand. All patients who were angiographically suitable
for XIENCETM V EECSS coronary artery stenting system were
evaluated for enrollment by each investigator. The registry
included patients 18 or over, with evidence of myocardial ischemia
(e.g., stable or unstable angina, or positive functional test or
reversible change in an electrocardiogram consistent with ische-
mia) with life expectancy of more than 5 years. Patients were also
required to accept CABG if indicated and agreed to undergo all
protocols required for follow-up procedures.
The exclusion criteria were (a) contraindications for dual
antiplatelet therapy, (b) history of everolimus hypersensitivity, (c)
participating in another device or drug study, (d) serious co-
morbidity disease (e.g., renal failure, liver failure), or (e) left
ventricular ejection fraction <20%.
Coronary angiography and percutaneous coronary intervention
procedure were performed according to the standard care at each
site. Lesion characteristics were recorded by each operator as per
the ACC/AHA classiﬁcation.5 Dual antiplatelet therapy was
recommended for at least 1 year after coronary stenting.
The THRIVE registry included information on age, sex, clinical
indications for PCI, presence or absence of heart failure, coronary
risk factors, renal disease, coronary anatomy, size and length of
stent, and complication(s) after the procedure.
Follow-up assessments were scheduled by clinic visit for
30 days, 6 months, 1 year, and 2 years after the coronary stenting
procedure.
The study was conducted according to the Helsinki Declaration
and the Good Clinical Practice Guidelines. Written informed
consent was obtained from each patient before performing the PCI
procedure. The institutional ethics committee reviewed and
approved the study protocol.
2.1. Study endpoint
The primary endpoint of this study was the composite of all-
cause mortality, myocardial infarction, and target lesion revascu-
larization at the 30-day, 1-year, and 2-year follow-up. The
secondary endpoint was a composite of major adverse cardiac
events (viz., cardiac death, myocardial infarction, and target lesion
revascularization) at the 30-day, 1-year, and 2-year follow-up.
2.2. Deﬁnitions
Death. All deaths were considered cardiac unless a deﬁnite
non-cardiac cause of death was evident (e.g., infection, cancer).
Cardiac death. Cardiac death was deﬁned as any death due to
immediate cardiac cause (e.g., myocardial infarction, sudden
death, or heart failure). Un-witnessed death and death of unknown
etiology were classiﬁed as cardiac death.
Myocardial infarction (MI). The deﬁnition of spontaneous MI
was deﬁned according to the Academic Research Consortium
(ARC).6 The level of troponin had to be 2 the upper reference
limit with chest pain. MI events not related to the PCI procedure
during the follow-up period represented a spontaneous myocar-
dial infarction.
Target lesion revascularization (TLR). TLR was deﬁned as any
repeat percutaneous intervention or bypass surgery of the target
vessel performed for restenosis or other complication of the target
lesion.Please cite this article in press as: Kiatchoosakun S, et al. A clinical eva
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repeat percutaneous intervention or bypass surgery of any
segment of the target vessel.
Stent thrombosis. Stent thrombosis was deﬁned as acute
(<24 h), subacute (24 h to 30 days), late (>30 days to 1 year), and
very late (>1 year). It was further deﬁned as per the ARC deﬁnition
as: (a) deﬁnite stent thrombosis (acute coronary syndrome and
angiographic or pathologic conﬁrmation); (b) probable stent
thrombosis (unexplained death without angiographic information
30 days after stent deployment); and, (c) possible stent
thrombosis (unexplained death >30 day after stent deployment).6
Clinical device success. Clinical device success was deﬁned as
<50% residual stenosis of the target lesion after stent deployment
was assessed by quantitative coronary angiography (QCA) or visual
estimation; i.e., when QCA was not available.
Clinical procedure success. Clinical procedure success was
deﬁned as successful deployment of the study stent with ﬁnal
residual stenosis being <50% of the lesion assessed by QCA or
visual estimation; i.e., when QCA was not available without
occurrence of death, MI, or TLR during hospitalization within a
maximum of 7 days after the PCI procedure.
Major adverse cardiac events (MACE). MACE was deﬁned as
the composite rate of cardiac death, MI, and TLR.
2.3. Study device
XIENCE V EES is a low proﬁle, ﬂexible, cobalt-chromium stent
coated with everolimus, which is released from a thin (7.8 mm),
biocompatible ﬂuoropolymer. The EES used in this study ranged
between 2.5 and 4.0 mm in diameter and between 8 and 28 mm in
length.
2.4. Data management
Data collection was conducted by well-trained nurses and
veriﬁed by the principle investigator at each site. Web-based,
double data entry was used to prevent data entry errors. Data were
collected then sent to an independent party for analysis.
2.5. Statistical analysis
Descriptive analyses were performed. Continuous variables are
presented as means  SD, and categorical variables as frequencies
and percentages.
3. Results
3.1. Patients and procedural characteristics
A total 400 patients were enrolled in the THRIVE study between
July 2008 and April 2011. At 2 years, 365 of the 400 patients (91%)
continued in the study. The patient follow-up ﬂow is presented in
Fig. 1. The baseline characteristics of all patients are shown in
Table 1. The mean age was 63 and 70% of the patients were male. A
respective 69 and 75% of patients presenting with hypertension
and dyslipidemia were receiving medical therapy. One-third of
patients were diabetic. Left ventricular ejection fraction averaged
55.9%. About one-half of patients presented with acute coronary
syndrome, while 15% had experienced myocardial infarction
before the indexing procedure. The majority (76%) had single
vessel disease and 14% had a history of heart failure within 2 weeks
before the procedure.
Procedural characteristics are presented in Table 2. Clinical
device success was 100% while clinical procedure success was
99.5%. Unplanned and urgent target vessel re-intervention wasluation of the XIENCE V everolimus eluting stent in the treatment
 – XIENCE V performance evaluation (THRIVE study), Indian Heart
Fig. 1. Patient ﬂow and follow up in THRIVE study through 2 years.
Table 3
Clinical outcome at 30 days, 1 year, and 2 year.
Outcomes 30 days
(N = 400) n (%)
1 year
(N = 377) n (%)
2 years
(N = 365) n (%)
All death 3 (0.7) 8 (2.1) 8 (2.2)
Cardiac death 2 (0.5) 3 (0.7) 3 (0.8)
MI 4 (1.0) 8 (2.1) 11 (3.0)
TLR 2 (0.5) 4 (1.0) 8 (2.1)
TVR 5 (1.2) 6 (1.6) 7 (1.9)
Any revascularizations 7 (1.7) 10 (2.6) 15 (4.1)
Composite of all death,
MI, and TLR
9 (2.2) 20 (5.3) 27 (7.3)
MACE (composite of
cardiac death,
MI, and TLR)
8 (2.0) 15 (3.9) 22 (6.0)
Stent thrombosis 2 (0.5) 4 (1.0) 6 (1.6)
Deﬁnite 2 (0.5) 2 (0.5) 2 (0.5)
Possible stent thrombosis 0 2 (0.5) 4 (1.0)
MI = myocardial infarction; TLR = target lesion revascularization; TVR = target vessel
revascularization; MACE = major adverse cardiac event.
Table 2
Procedural characteristics.
Variables n (%) or mean  SD
Clinical procedure success 398 (99.5)
Clinical device success 400 (100)
Treated lesion
LAD 271 (45.5)
LCX 96 (16.1)
RCA 158 (26.5)
Left main 21 (3.5)
Saphenous vein graft 4 (0.6)
Others 46 (7.7)
Lesion class B2/C 249 (41.7)
Stents implanted per patient 1.62  0.85
Reference vessel diameter (mm) 2.71  0.78
Stent length (mm) 20.20  5.70
Most frequent stent length implanted (28 mm) 169 (24.4)
Stent diameter (mm) 2.96  0.46
Most frequent stent diameter (3.0 mm) 197 (28.4)
Unplanned urgent PCI during hospitalization 2 (0.5)
Death 0 (0)
Stroke 0 (0)
LAD = left anterior descending artery; LCX = left circumﬂex artery; RCA = right
coronary artery.
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occurred immediately after the procedure.
The coronary angiography data revealed that 41.7% of coronary
lesions were class B2/C, according to the American College of
Cardiology/American Heart Association, and 45% of the treated
lesions were in the left anterior descending artery. The mean
diameter and mean length of stent were 2.9 mm and 20 mm,
respectively. There was no in-hospital mortality in this registry.
3.2. Clinical outcomes
The clinical outcomes are presented in Table 3. The primary
endpoint (all-cause mortality, MI, and TLR) at 30 days was 2.2%. At
1 year, the respective rate of all-cause mortality, MI, and TLR was
2.1%, 2.1%, and 1.0%. At 2 years, the respective rate of totalTable 1
Baseline characteristics.
Clinical variables Mean  SD or n (%)
Age, mean (SD) 63.3  10.6
Men (n, %) 281 (70.3)
Diabetes mellitus, n (%) 140 (35.0)
Chronic kidney disease, n (%) 43 (4.8)
Hypertension requiring medication, n (%) 277 (69.3)
Dyslipidemia requiring medication, n (%) 300 (75.0)
Current smoking, n (%) 65 (16.3)
Family history of premature atherosclerosis, n (%) 31 (7.8)
Prior myocardial infarction, n (%) 62 (15.5)
History of heart failure within 2 weeks, n (%) 56 (14)
Left ventricular ejection fraction, mean (SD) 55.9  15.1
Acute coronary syndrome, n (%) 202 (50.5)
ST elevation MI, n (%) 84 (21)
Non-ST elevation MI, n (%) 83 (20.8)
Unstable angina, n (%) 35 (8.8)
Number of disease vessels
Single vessel, n (%) 305 (76.3)
Double vessels, n (%) 84 (21.0)
Triple vessels, n (%) 11 (2.8)
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cardiac death rate at 30 days, 1 year, and 2 years was 0.5%, 0.7%, and
0.8%. The rate of major adverse cardiac events (cardiac death, MI,
and TLR) at 30 days, 1 year, and 2 years was 2.0%, 3.9%, and 6.0%,
respectively. Deﬁnite acute stent thrombosis was conﬁrmed in
2 patients during the repeated emergency PCI procedure. The
cumulative rate of stent thrombosis was 1.6% at 2 years follow-up.
The possibility of very late stent thrombosis occurred in 2 patients
(0.5%) at the 2-year follow-up.
4. Discussion
The present study demonstrates that the XIENCE VTM EES is safe
and efﬁcacious, when applied in daily practice in Thai population.
The two-year rates for all-cause mortality, myocardial infarction,
and target lesion revascularization related to XIENCE VTM EES were
low and consistent with those in clinical randomized controlled
trials of this stent.
Compared to the SPIRIT V study,7 the THRIVE study population
included a greater proportion of high-risk patients, including 50%
of acute coronary syndrome, 35% of diabetic patients, and 41.7% of
type B2 or C lesions.
The results of the present data are consistent with those
reported in the SPIRIT trials. At 1 year, the rate of major adverseluation of the XIENCE V everolimus eluting stent in the treatment
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sustained at the 2-year follow-up.4 The cardiac death rate in the
THRIVE study is lower compared to the SPIRIT III study—a
randomized control trial, comparing the EES to paclitaxel eluting
stent system in 1002 patients. The respective cardiac death rate at
2 years was 1.1% and 1.3%, while the MI rate was 3.3 and 5.5%.8 The
SPIRIT IV trial—a large scale randomized trial in more complex
lesions—reported a 1-year rate of primary endpoint (cardiac death,
ischemic driven revascularization, and target vessel MI) of 3.9% in
3690 patients.9 In the SPIRIT V study—a multi-center prospective,
post-market surveillance—the respective 1-year rate of cardiac
death, MI, and TLR was 1.1%, 3.5% and 1.8%.7
The COMPARE Trial was a 2-year follow-up of a randomized
controlled trial of everolimus and placitaxel eluting stents for
coronary revascularization in daily practice. It was performed in
all-comers without any exclusion criteria—other than general
contraindications for DES. The trial showed that the rate of all-
death, non-fatal MI, and target vessel revascularization occurred in
9.0% of everolimus eluting stent patients and 13.7% of placitaxel
eleuting stents.10,11
Stent thrombosis—the rare but fatal complication of DES—is a
major concern following stent implantation. The incidence of stent
thrombosis was markedly reduced (nearly 75%) in XIENCE V EES
compared to PES in two large clinical trials.7,12 The respective rate
of stent thrombosis for patients treated with EES and PES was 0.7%
and 2.5%. It is estimated that for 1000 non-diabetic patients treated
with everolimus eluting stent—over against the paclitaxel eluting
stent—about 14 stent thromboses would be prevented.13 The rate
of deﬁnite stent thrombosis at 1 year in the present study was 0.5%,
which is comparable to the 0.3% reported in the SPIRIT V trial.7 The
low rate of stent thrombosis in patients treated with XIENCE V EES
is likely due to the combination of fracture resistant cobalt-
chromium struts in the everolimus elution, and the thrombo-
resistant property of the ﬂuorinated polymer.14
The TLR rate at 1 year and 2 years in this present study (1.0% and
2.1% respectively) was comparable with previous studies among a
similar population.15,16 The data from XIENCE India showed that
the TLR rate at 1 year and 2 years were 1.4% and 1.6%,
respectively.16 The rate of TLR in the current study, however,
may be underestimated as there was no angiographic follow-up; as
per protocol, all revascularizations were considered ischemic and
symptomatic driven. In addition, troponin levels and EKGs were
not routinely measured during follow-up visits.
The safety and efﬁcacy of XIENCE VTM EES have been evaluated
in different populations. The XIENCE V USA—a post market study—
included 5054 patients in the United States.17 The rate of stent
thrombosis in that study was 0.84% at 1 year while the rate of
composite endpoint (cardiac death and stent thrombosis) was 6.5%
in the general population. In the Indian real-world study of XIENCE
V EES, Seth et al. reported that the rate of stent thrombosis at 1 year
was 0.51%, while the respective rate of cardiac death at 2 years and
3 years was 2.7% and 3.1%.16
The results of the THRIVE study ﬁlled the gap between the
highly selected patients randomized control trials and patients in
routine daily practice of interventional cardiology. The broad
spectrum of inclusion criteria in the THRIVE study increased the
number of patients beneﬁtting from XIENCE VTM EES that might
previously have been left out of previous trials.18–20
5. Conclusion
The 2-year results from the THRIVE study indicate that the use
of XIENCE V EES in real-world population with wide ranging
severity of coronary artery disease is safe and effective. The results
are comparable to previous well-controlled studies.Please cite this article in press as: Kiatchoosakun S, et al. A clinical eva
of patients with coronary artery disease: Result from Thailand Registry
J. (2016), http://dx.doi.org/10.1016/j.ihj.2016.10.0086. Study limitations
There are several limitations that have to be taken into
consideration when interpreting the results of this study. First, a
single arm study design that lacks a control arm for direct
comparison has an inherent bias. Second, since each investigator
assessed lesion characteristics at the time of procedure without
agreement from another investigator, there has been no calibration
between investigators, leading to inconsistency in assessments.
Third, the study design was not completely suitable for all comers,
we cannot exclude the possibility that the low event rate might be
related to a selection bias.
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